VCYT icon

Veracyte

31.28 USD
+0.68
2.22%
Updated Apr 22, 12:30 PM EDT
1 day
2.22%
5 days
-1.94%
1 month
-5.67%
3 months
-27.34%
6 months
-4.05%
Year to date
-22.65%
1 year
57.58%
5 years
33.73%
10 years
283.80%
 

About: Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Employees: 824

0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,042% more call options, than puts

Call options by funds: $8.4M | Put options by funds: $736K

116% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 25

25% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]

17% more capital invested

Capital invested by funds: $2.78B [Q3] → $3.25B (+$471M) [Q4]

8% more funds holding

Funds holding: 290 [Q3] → 314 (+24) [Q4]

0.52% more ownership

Funds ownership: 106.74% [Q3] → 107.26% (+0.52%) [Q4]

14% less repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 119

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$37
18%
upside
Avg. target
$45
45%
upside
High target
$51
63%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
Guggenheim
Subbu Nambi
20% 1-year accuracy
4 / 20 met price target
18%upside
$37
Buy
Maintained
9 Apr 2025
Stephens & Co.
Mason Carrico
12% 1-year accuracy
3 / 26 met price target
44%upside
$45
Overweight
Reiterated
26 Mar 2025
Craig-Hallum
John Wilkin
0% 1-year accuracy
0 / 3 met price target
44%upside
$45
Buy
Initiated
20 Mar 2025
UBS
Lu Li
0% 1-year accuracy
0 / 3 met price target
57%upside
$49
Buy
Maintained
25 Feb 2025
Needham
Mike Matson
22% 1-year accuracy
27 / 121 met price target
63%upside
$51
Buy
Reiterated
25 Feb 2025

Financial journalist opinion

Based on 11 articles about VCYT published over the past 30 days

Neutral
Business Wire
3 hours ago
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing Will Be Presented at AUA Annual Meeting.
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
Neutral
Business Wire
20 hours ago
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to National Cancer Institute's SEER Specialized Database Release.
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release
Positive
Investors Business Daily
5 days ago
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
Positive
Zacks Investment Research
5 days ago
Should You Continue to Hold Veracyte Stock in Your Portfolio?
Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.
Should You Continue to Hold Veracyte Stock in Your Portfolio?
Positive
Zacks Investment Research
1 week ago
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
Positive
Zacks Investment Research
1 week ago
Here's Why Veracyte (VCYT) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Veracyte (VCYT) is a Strong Growth Stock
Positive
Zacks Investment Research
1 week ago
Veracyte (VCYT) Just Overtook the 20-Day Moving Average
After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Veracyte (VCYT) Just Overtook the 20-Day Moving Average
Positive
Zacks Investment Research
1 week ago
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?
Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?
Positive
Zacks Investment Research
3 weeks ago
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue?
Positive
Zacks Investment Research
3 weeks ago
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade
The mean of analysts' price targets for Veracyte (VCYT) points to a 35.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade
Charts implemented using Lightweight Charts™